Neuromuscular Blocking Agents

  • Rafael A. Ortega
  • Gerardo Rodríguez
  • Rubén Azocar


Neuromuscular blocking agents have, perhaps, the most fascinating history among the drugs used in anesthesiology and intensive care. For centuries, South American aborigines had used curare to hunt animals before Claude Bernard showed in 1850 that these drugs act peripherally, blocking conduction where motor nerves meet the muscle.1 These historical facts should serve to remind us that this group of drugs is lethal when misused and that while paralysis occurs, intellectual function remains unaffected.


Intensive Care Unit Neuromuscular Blockade Neuromuscular Blocking Acetylcholinesterase Inhibitor Neuromuscular Blocking Agent 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Viby-Mogensen J. Neuromuscular transmission and neuromuscular disease. In: Healy TE, Cohen PJ, editors. Wylie and Churchill-Davidson’s A practice of anaesthesia. 6th ed. London: A Hodder Arnold Publication; 1995. p. 128–146.Google Scholar
  2. 2.
    Aitkenhead AR. Awareness during anaesthesia: when is an anaesthetic not an anaesthetic? Can J Anaesth. 1996;43:206–211.PubMedCrossRefGoogle Scholar
  3. 3.
    Johnson KL, Cheung RB, Johnson SB, et al. Therapeutic paralysis of critically ill patients: perceptions of patients and their family members. Am J Crit Care. 1999;8:490–499.PubMedGoogle Scholar
  4. 4.
    Sharpe MD. The use of muscle relaxants in the intensive care unit. Can J Anaesth. 1992;39:949–962.PubMedCrossRefGoogle Scholar
  5. 5.
    Davidson JE. Neuromuscular blockade: indications, peripheral nerve stimulation, and other concurrent interventions. New Horiz. 1994;2:75–84.PubMedGoogle Scholar
  6. 6.
    Murray MJ, Cowen J, DeBlock H, et al. Clinical practice guidelines for sustained neuromuscular blockade in the adult critically ill patient. Crit Care Med. 2002;30(1):142–156.PubMedCrossRefGoogle Scholar
  7. 7.
    Sladen RN. Neuromuscular blocking agents in the intensive care unit: a two-edged sword. Crit Care Med. 1995;23:423–428.PubMedCrossRefGoogle Scholar
  8. 8.
    Sapirstein A, Hurtford WE. Neuromuscular blocking agents in the management of respiratory failure. Indications and treatment guidelines. Crit Care Clin. 1994;10:831–843.PubMedGoogle Scholar
  9. 9.
    Murray MJ, Coursin DB, Scuderi PE, et al. Double-blind, randomized, multicenter study of doxacurium vs. pancuronium in intensive care unit patients who require neuromuscular-blocking agents. Crit Care Med. 1995;23:450–458.PubMedCrossRefGoogle Scholar
  10. 10.
    Anandaciva S, Koay CW. Tetanus and rocuronium in the intensive care unit. Anaesthesia. 1996;51:505–506.PubMedCrossRefGoogle Scholar
  11. 11.
    Ohlinger MJ, Rhoney DH. Neuromuscular blocking agents in the neurosurgical intensive care unit. Surg Neurol. 1998;49:217–221.PubMedCrossRefGoogle Scholar
  12. 12.
    Prielipp RC, Coursin DB. Sedative and neuromuscular blocking drug use in critically ill patients with head injuries. New Horiz. 1995;3:456–468.PubMedGoogle Scholar
  13. 13.
    Nearman HS, Eckhauser ML. Postoperative management of a severely anemic Jehovah’s Witness. Crit Care Med. 1983;11:142–143.PubMedCrossRefGoogle Scholar
  14. 14.
    Guyton AC. Neuromuscular transmission: function of smooth muscle. In: Guyton AC, editor. Textbook of medical physiology. 7th ed. Philadelphia: W.B. Saunders; 1986. p. 136–147.Google Scholar
  15. 15.
    Reeves ST, Turcasso NM. Nondepolarizing neuromuscular blocking agents in the intensive care unit: a clinical review. South Med J. 1997;90:769–774.PubMedCrossRefGoogle Scholar
  16. 16.
    Stoelting RK. Neuromuscular-blocking drugs. In: Stoelting RK, editor. Pharmacology and physiology in anesthetic practice. 3rd ed. Philadelphia, PA: Lippincott-Raven Publishers; 1999. p. 182–223.Google Scholar
  17. 17.
    Armstrong DK, Crisp CB. Pharmacoeconomic issues of sedation, analgesia and neuromuscular blockade in critical care. New Horiz. 1994;2:85–93.PubMedGoogle Scholar
  18. 18.
    Hughes M, Grant IS, Biccard B, et al. Suxametonium and critical illness polyneuropathy. Anaesth Intensive Care. 1999;27:636–638.PubMedGoogle Scholar
  19. 19.
    Wright PM, Brown R, Lau M, et al. A pharmacodynamic explanation for the rapid onset/offset of rapacuronium bromide. Anesthesiology. 1999;90:16–23.PubMedCrossRefGoogle Scholar
  20. 20.
    Levy JH, Pitts M, Thanopoulos A, et al. The effects of rapacuronium on histamine release and hemodynamics in adult patients undergoing general anesthesia. Anesth Analg. 1999;89:290–295.PubMedGoogle Scholar
  21. 21.
    Grigore AM, Brusco L Jr, Kuroda M, et al. Laudanosine and atracurium concentrations in a patient receiving long-term atracurium infusion. Crit Care Med. 1998;26:180–183.PubMedCrossRefGoogle Scholar
  22. 22.
    Kisor DF, Schmith VD. Clinical pharmacokinetics of cisatracurium besilate. Clin Pharmacokinet. 1999;36:27–40.PubMedCrossRefGoogle Scholar
  23. 23.
    Newman PJ, Quinn AC, Grounds RM, et al. A comparison of cisatracurium (51W89) and atracurium by infusion in critically ill patients. Crit Care Med. 1997;25:1139–1142.PubMedCrossRefGoogle Scholar
  24. 24.
    Pearson AJ, Harper NJ, Pollard BJ. The infusion requirements and recovery characteristics of cisatracurium or atracurium in intensive care patients. Intensive Care Med. 1996;22:694–698.PubMedCrossRefGoogle Scholar
  25. 25.
    Prielipp RC, Robinson JC, Wilson JA, et al. Dose response, recovery, and cost of doxacurium as a continuous infusion in neurosurgical intensive care unit patients. Crit Care Med. 1997;25:1236–1241.PubMedCrossRefGoogle Scholar
  26. 26.
    Cook DR, Freeman JA, Lai AA, et al. Pharmacokinetics and pharmacodynamics of doxacurium in normal patients and in those with hepatic or renal failure. Anesth Analg. 1991;72:145–150.PubMedCrossRefGoogle Scholar
  27. 27.
    Ostergaard D, Jensen FS, Jensen E, et al. Mivacurium-induced neuromuscular blockade in patients with atypical plasma cholinesterase. Acta Anaesthesiol Scand. 1993;37:314–318.PubMedCrossRefGoogle Scholar
  28. 28.
    Khuenl-Brady KS, Reitstatter B, Schlager A, et al. Long-term administration of pancuronium and pipecuronium in the intensive care unit. Anesth Analg. 1994;78:1082–1086.PubMedCrossRefGoogle Scholar
  29. 29.
    Sparr HJ, Mellinghoff H, Blobner M, et al. Comparison of intubating conditions after rapacuronium (Org 9487) and succinylcholine following rapid sequence induction in adult patients. Br J Anaesth. 1999;82:537–541.PubMedCrossRefGoogle Scholar
  30. 30.
    Purdy R, Bevan DR, Donati F, et al. Early reversal of rapacuronium with neostigmine. Anesthesiology. 1999;91:51–57.PubMedCrossRefGoogle Scholar
  31. 31.
    Sparr HJ, Wierda JM, Proost JH, et al. Pharmacodynamics and pharmacokinetics of rocuronium in intensive care patients. Br J Anaesth. 1997;78:267–273.PubMedCrossRefGoogle Scholar
  32. 32.
    Prielipp RC, Coursin DB, Scuderi PE, et al. Comparison of the infusion requirements and recovery profiles of vecuronium and cisatracurium 51W89 in intensive care unit patients. Anesth Analg. 1995;81:3–12.PubMedGoogle Scholar
  33. 33.
    Khuenl-Brady KS, Sparr H, Puhringer F, et al. Rocuronium bromide in the ICU: dose finding and pharmacokinetics. Eur J Anaesthesiol Suppl. 1995;11:79–80.PubMedGoogle Scholar
  34. 34.
    de Lemos JM, Carr RR, Shalansky KF, et al. Paralysis in the critically ill: intermittent bolus pancuronium compared with continuous infusion. Crit Care Med. 1999;27:2648–2655.PubMedCrossRefGoogle Scholar
  35. 35.
    Light RW, Bengfort JL, George RB. The adult respiratory distress syndrome and pancuronium bromide. Anesth Analg. 1975;54:219–223.PubMedCrossRefGoogle Scholar
  36. 36.
    Murray MJ. Monitoring of peripheral nerve stimulation versus standard clinical assessment for dosing of neuromuscular blocking agents. Crit Care Med. 1997;25:561–562.PubMedCrossRefGoogle Scholar
  37. 37.
    Segredo V, Matthay MA, Sharma ML, et al. Prolonged neuromuscular blockade after long-term administration of vecuronium in two critically ill patients. Anesthesiology. 1990;72:566–570.PubMedCrossRefGoogle Scholar
  38. 38.
    Meyer KC, Prielipp RC, Grossman JE, et al. Prolonged weakness after infusion of atracurium in two intensive care unit patients. Anesth Analg. 1994;78:772–774.PubMedCrossRefGoogle Scholar
  39. 39.
    Prielipp RC, Coursin DB, Wood KE, et al. Complications associated with sedative and neuromuscular blocking drugs in critically ill patients. Crit Care Clin. 1995;11(4):983–1003.PubMedGoogle Scholar
  40. 40.
    Klessig HT, Geiger HJ, Murray MJ, et al. A national survey on the practice patterns of anesthesiologist intensivists in the use of muscle relaxants. Crit Care Med. 1992;20:1341–1345.PubMedCrossRefGoogle Scholar
  41. 41.
    Kleinpell R, Bedrosian C, McCormick L, et al. Use of peripheral nerve stimulators to monitor patients with neuromuscular blockade in the ICU. Am J Crit Care. 1996;5:449–454.PubMedGoogle Scholar
  42. 42.
    Rudis MI, Guslits BJ, Peterson EL, et al. Economic impact of prolonged motor weakness complicating neuromuscular blockade in the intensive care unit. Crit Care Med. 1996;24:1749–1756.PubMedCrossRefGoogle Scholar
  43. 43.
    Frankel H, Jeng J, Tilly E, et al. The impact of implementation of neuromuscular blockade monitoring standards in a surgical intensive care unit. Am Surg. 1996;62:503–506.PubMedGoogle Scholar
  44. 44.
    Rudis MI, Sikora CA, Angus E, et al. A prospective, randomized, controlled evaluation of peripheral nerve stimulation versus standard clinical dosing of neuromuscular blocking agents in critically ill patients. Crit Care Med. 1997;25:575–583.PubMedCrossRefGoogle Scholar
  45. 45.
    Donati F, Antzaka C, Bevan DR. Potency of pancuronium at the diaphragm and the adductor pollicis muscle in humans. Anesthesiology. 1986;65:1–5.PubMedCrossRefGoogle Scholar
  46. 46.
    Donati F, Meistelman C, Plaud B. Vecuronium neuromuscular blockade at the diaphragm, the orbicularis oculi, and adductor pollicis muscles. Anesthesiology. 1990;73:870–875.PubMedCrossRefGoogle Scholar
  47. 47.
    de Rossi L, Fritz H, Krober L, et al. Cisatricurium in the orbicularis oculi muscle. Comparison of the neuromuscular action of cisatracurium and atracurium in the orbicularis oculi muscle and the adductor pollicis muscle. Anaesthesist. 1999;48:602–606.PubMedCrossRefGoogle Scholar
  48. 48.
    Rudis MI, Guslits BG, Zarowitz BJ. Technical and interpretive problems of peripheral nerve stimulation in monitoring neuromuscular blockade in the intensive care unit. Ann Pharmacother. 1996;30:165–172.PubMedGoogle Scholar
  49. 49.
    Segredo V, Caldwell JE, Matthay MA, et al. Persistent paralysis in critically ill patients after long-term administration of vecuronium. N Engl J Med. 1992;327:524–528.PubMedCrossRefGoogle Scholar
  50. 50.
    Watling SM, Dasta JF. Prolonged paralysis in intensive care unit patients after the use of neuromuscular blocking agents: a review of the literature. Crit Care Med. 1994;22:884–893.PubMedCrossRefGoogle Scholar
  51. 51.
    Hoyt JW. Persistent paralysis in critically ill patients after the use of neuromuscular blocking agents. New Horiz. 1994;2:48–55.PubMedGoogle Scholar
  52. 52.
    Prielipp R, Jackson MJ, Coursin D. Comparison of neuromuscular recovery after paralysis with atracurium versus vecuronium in an ICU patient with renal insufficiency. Anesth Analg. 1994;78:775–778.PubMedCrossRefGoogle Scholar
  53. 53.
    Sokoll MD, Gergis SD. Antibiotics and neuromuscular function. Anesthesiology. 1981;55:148–159.PubMedCrossRefGoogle Scholar
  54. 54.
    Fuchs-Buder T, Suter PM. Recovery properties of cisatracurium and vecuronium in intensive care unit patients. Anesth Analg. 1996;82:892–893.PubMedGoogle Scholar
  55. 55.
    Erkola O. Complications of neuromuscular blockers: Interaction with concurrent medications and other neuromuscular blockers. Anesthesiol Clin North America. 1993;11:427–442.Google Scholar
  56. 56.
    Lewis KS, Rothenberg DM. Neuromuscular blockade in the intensive care unit. Am J Health Syst Pharm. 1999;56:72–75.PubMedGoogle Scholar
  57. 57.
    Hirano M, Ott BR, Raps EC, et al. Acute quadriplegic myopathy: a complication of treatment with steroids, nondepolarizing blocking agents, or both. Neurology. 1992;42:2082–2087.PubMedCrossRefGoogle Scholar
  58. 58.
    Hund E. Myopathy in critically ill patients. Crit Care Med. 1999;27:2544–2547.PubMedCrossRefGoogle Scholar
  59. 59.
    Fischer JR, Baer RK. Acute myopathy associated with combined use of corticosteroids and neuromuscular blocking agents. Ann Pharmacother. 1996;30:1437–1445.PubMedGoogle Scholar
  60. 60.
    David WS, Roehr CL, Leatherman JW. EMG findings in acute myopathy with status asthmaticus, steroids and paralytics. Clinical and electrophysiologic correlation. Electromyogr Clin Neurophysiol. 1998;38:371–376.PubMedGoogle Scholar
  61. 61.
    Lacomis D, Giuliani MJ, Van Cott A, et al. Acute myopathy of intensive care: clinical, electromyographic, and pathological aspects. Ann Neurol. 1996;40:645–654.PubMedCrossRefGoogle Scholar
  62. 62.
    Zochodne DW, Ramsay DA, Saly V, et al. Acute necrotizing myopathy of intensive care: electrophysiological studies. Muscle Nerve. 1994;17:285–292.PubMedCrossRefGoogle Scholar
  63. 63.
    Helliwell TR, Coakley JH, Wagenmakers AJ, et al. Necrotizing myopathy in critically-ill patients. J Pathol. 1991;164:307–314.PubMedCrossRefGoogle Scholar
  64. 64.
    Larsson L, Li X, Edstrom L, et al. Acute quadriplegia and loss of muscle myosin in patients treated with nondepolarizing neuromuscular blocking agents and corticosteroids: mechanisms at the cellular and molecular levels. Crit Care Med. 2000;28:34–45.PubMedCrossRefGoogle Scholar
  65. 65.
    Griffin D, Fairman N, Coursin D, et al. Acute myopathy during treatment of status asthmaticus with corticosteroids and steroidal muscle relaxants. Chest. 1992;102:510–514.PubMedCrossRefGoogle Scholar
  66. 66.
    Lacomis D, Smith TW, Chad DA. Acute myopathy and neuropathy in status asthmaticus: case report and literature review. Muscle Nerve. 1993;16:84–90.PubMedCrossRefGoogle Scholar
  67. 67.
    Behbehani NA, Al-Mane F, D’yachkova Y, et al. Myopathy following mechanical ventilation for acute severe asthma: the role of muscle relaxants and corticosteroids. Chest. 1999;115:1627–1631.PubMedCrossRefGoogle Scholar
  68. 68.
    Rouleau G, Karpati G, Carpenter S, et al. Glucocorticoid excess induces preferential depletion of myosin in denervated skeletal muscle fibers. Muscle Nerve. 1987;10:428–438.PubMedCrossRefGoogle Scholar
  69. 69.
    Tousignant CP, Bevan DR, Eisen AA, et al. Acute quadriparesis in an asthmatic treated with atracurium. Can J Anaesth. 1995;42:224–227.PubMedCrossRefGoogle Scholar
  70. 70.
    Davis NA, Rodgers JE, Gonzalez ER, et al. Prolonged weakness after cisatracurium infusion: a case report. Crit Care Med. 1998;26:1290–1292.PubMedCrossRefGoogle Scholar
  71. 71.
    Hoke A, Rewcastle NB, Zochodne DW. Acute quadriplegic myopathy unrelated to steroids or paralyzing agents: quantitative EMG studies. Can J Neurol Sci. 1999;26:325–329.PubMedGoogle Scholar
  72. 72.
    Miro O, Salmeron JM, Masanes F, et al. Acute quadriplegic myopathy with myosin-deficient muscle fibers after liver transplantation: defining the clinical picture and delimiting the risk factors. Transplantation. 1999;67:1144–1151.PubMedCrossRefGoogle Scholar
  73. 73.
    Stoelting RK. Anticholinesterase drugs and cholinergic agonists. In: Stoelting RK, editor. Pharmacology and physiology in anesthetic practice. 3rd ed. Philadelphia, PA: Lippincott-Raven Publishers; 1999. p. 224–237.Google Scholar
  74. 74.
    de Boer HD, van Egmond J, van de Pol F, et al. Chemical encapsulation of rocuronium by synthetic cyclodextrin derivatives: reversal of neuromuscular block in anaesthetized Rhesus monkeys. Br J Anaesth. 2006;96:201–206.PubMedCrossRefGoogle Scholar
  75. 75.
    Groudine SB, Soto R, Lien C, et al. A randomized, dose-finding, phase II study of the selective relaxant binding drug, Sugammadex, capable of safely reversing profound rocuronium-induced neuromuscular block. Anesth Analg. 2007;104(3):555–562.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  • Rafael A. Ortega
    • 1
  • Gerardo Rodríguez
    • 1
  • Rubén Azocar
    • 2
  1. 1.Department of Anesthesiology, Boston Medical CenterBoston UniversityBostonUSA
  2. 2.Department of AnesthesiologyBoston University School of MedicineBostonUSA

Personalised recommendations